Squamous Cell Cancer Clinical Trial
Official title:
Open-label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
The purpose of this open-label, randomized, controlled, Phase 1/2 study of the integrin
inhibitor cilengitide is to evaluate the safety and efficacy of the combination of different
regimens of cilengitide added to cisplatin, 5-fluorouracil (5-FU), and cetuximab in
participants with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).
The Phase 1 part was conducted in dedicated study centers. In the Phase 2 part of this
trial, cilengitide is administered at two different doses to two experimental groups. The
third group will only receive cisplatin, 5-FU and cetuximab. In the Phase 1 part of this
trial, the dose of cilengitide in combination with cisplatin, 5-FU and cetuximab was
determined.
Cilengitide is an experimental anti-cancer substance interacting with so-called integrins.
Integrins are protein molecules that are known to be present on the surface of certain
cancer cells. Integrins are also found on certain cells that belong to growing blood vessels
(endothelial cells). Integrins potentially facilitate the blood vessels' support of the
tumor (angiogenesis) as well as the tumor's growth and further spread throughout the body
(metastasis). By inhibiting integrins on the tumor cell surface, cilengitide potentially
kills cancer cells, and potentially sensitizes cancer cells to other co-administered
therapeutics. By inhibiting integrins on the endothelial cell surface, it potentially
inhibits the ingrowth of additional blood vessels towards the tumor.
Cilengitide is given as an intravenous infusion (given by a drip in one vein of your arm).
If any unacceptable side effect occurs, treatment with the study drug will be stopped.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01358097 -
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
|
N/A | |
| Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01721525 -
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
|
Phase 1 | |
| Completed |
NCT01016769 -
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
|
Phase 1/Phase 2 | |
| Completed |
NCT00661427 -
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Completed |
NCT00382031 -
Zalutumumab in Patients With Non-curable Head and Neck Cancer
|
Phase 3 | |
| Recruiting |
NCT04391049 -
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
|
Phase 1 | |
| Recruiting |
NCT05932511 -
Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
|
Early Phase 1 | |
| Not yet recruiting |
NCT06398418 -
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00815295 -
Study of Sorafenib/Cetuximab in Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00542308 -
Zalutumumab in Non-curable Patients With SCCHN
|
Phase 2 | |
| Completed |
NCT00485485 -
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Terminated |
NCT02376699 -
Safety Study of SEA-CD40 in Cancer Patients
|
Phase 1 | |
| Completed |
NCT00255476 -
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
|
Phase 2 | |
| Recruiting |
NCT03935893 -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
|
Phase 2 | |
| Terminated |
NCT00401401 -
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00559351 -
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
|
Phase 3 | |
| Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03509467 -
Using MC1R Genotype to Impact Melanoma Risk Behavior
|
N/A | |
| Completed |
NCT01384708 -
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
|
Phase 0 |